Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluation of hypnosis therapy efficacy in addition to pharmacologic standard treatment of Croh disease during remission by the evaluation of quality of life;
Crohn disease is defined as an inflammatory chronic disease of the bowel characterize by intermittent flare-ups and remission periods.
Crohn disease is due to genetic and environmental factors such as stress. Stress is an important aggravation factor of the disease symptoms which can stop a remission period and induce a relapse into a flare-up period.
Hypnosis is a non-medicinal technic which already show efficacy in the treatment of functional digestive troubles. These diseases are bio/psycho/social models such as Crohn disease.
Hypnosis can reduce visceral pain sensibility, reduce stress and reduce pro-inflammatory cytokines liberation into intestinal mucosa.
Though, only few data are available on hypnosis interest in the treatment of Crohn disease and inflammatory bowel diseases as it is often isolated clinical case report.
One study on patients with rectocolitis in remission period has been done recently and show that hypnosis increased the duration of the remission period.
The principal objective of this study is to evaluate hypnosis efficacy in term of quality of life for patients with Crohn disease during remission.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| immunosuppressor/TNFalpha | Active Comparator | Standard treatment with immunosuppressor and/or anti-TNFalpha treatment. |
|
| Hypnosis + Standard Treatment | Experimental | Standard treatment with immunosuppressor and/or anti-TNFalpha treatment in addition to hypnosis parallel treatment. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| immunosuppressor/TNFalpha | Drug | Standard Treatment : immunosuppressor/TNFalpha as in standard practice |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mid term hypnosis efficacy with IBDQ | Efficacy evaluation of hypnosis 6 months after the beginning of hypnosis sessions on the quality of life with Inflammatory Bowel Disease Questionnaire (IBDQ) | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Short term hypnosis efficacy with IBDQ | Efficacy evaluation of hypnosis 3 months after the beginning of hypnosis sessions on the quality of life with Inflammatory Bowel Disease Questionnaire (IBDQ) | 3 months |
| Disease acceptance with ICQ-18 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Bruno BONAZ, PU-PH | Contact | 04 76 76 55 97 | BBonaz@chu-grenoble.fr | |
| Nicolas GONNET | Contact | NGonnet@chu-grenoble.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital | Recruiting | Grenoble | 38000 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40243391 | Derived | Tiles-Sar N, Neuser J, de Sordi D, Baltes A, Preiss JC, Moser G, Timmer A. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2025 Apr 17;4(4):CD006913. doi: 10.1002/14651858.CD006913.pub3. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014409 | Tumor Necrosis Factor-alpha |
| D006990 | Hypnosis |
| ID | Term |
|---|---|
| D006023 | Glycoproteins |
| D006001 | Glycoconjugates |
| D002241 | Carbohydrates |
| D015846 | Monokines |
Not provided
Not provided
Prospective study, monocentric, controlled, randomized, open-label
Not provided
Not provided
Not provided
Not provided
| Hypnosis | Behavioral | 8 hypnosis group sessions during 2 months |
|
Impact of hypnosis on the disease acceptance short and mid term with the Evolution of the Illness Cognition Questionnaire for chronic disease
| 3 months and 6 months |
| Clinical score with Harvey-Bradshaw Index short and mid term | Evolution of the clinical score short and mid term with Harvey-Bradshaw Index | 3 months and 6 months |
| Vagal tonus with electrocardiogram | Evolution of the vagal tonus with electrocardiogram short and mid term | 3 months and 6 months |
| Inflammatory status with C Reactive Protein | Evolution of the C Reactive Protein concentration in the plasma | 3 months and 6 months |
| Stress with Perceived Stress Scale | Evolution of stress status short and mid term with Perceived Stress Scale which goes from 10 to 50. Lower values represent better outcome. | 3 months and 6 months |
| Fatigue with Multidimensional Fatigue Inventory | Evolution of fatigue status short and mid term | 3 months and 6 months |
| Long term hypnosis efficacy | Efficacy evaluation of hypnosis 12 months after the beginning of hypnosis sessions on the quality of life with Inflammatory Bowel Disease Questionnaire (IBDQ) which goes from 32 to 224. Higher values represent better outcome. | 12 months |
| Clinical score with Harvey-Bradshaw Index long term | Evolution of the clinical score long term with Harvey-Bradshaw Index | 12 months |
| D007410 | Intestinal Diseases |
| D016207 |
| Cytokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D048069 | Tumor Necrosis Factors |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D001685 | Biological Factors |
| D026441 | Mind-Body Therapies |
| D000529 | Complementary Therapies |
| D013812 | Therapeutics |
| D011613 | Psychotherapy |
| D004191 | Behavioral Disciplines and Activities |